Tocilizumab administration in a refractory case of COVID-19

Int J Antimicrob Agents. 2020 Aug;56(2):106043. doi: 10.1016/j.ijantimicag.2020.106043. Epub 2020 Jun 2.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Betacoronavirus / isolation & purification*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / pathology
  • Cytokine Release Syndrome / drug therapy*
  • Humans
  • Immunologic Factors / administration & dosage*
  • Lung / diagnostic imaging
  • Lung / pathology
  • Male
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Radiography, Thoracic
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • tocilizumab